EEF1A1 and AL amyloidosis: Among them, plitidepsin was approved in Australia for combined treatment of relapsed/refractory multiple myeloma with dexamethasone [41], thus providing initial proof of principle that eEF1A inhibitors can achieve the desired therapeutic efficacy with safety.